Dr. Brian Abbott is a medical professional with over 25 years of experience in hematology oncology, including thirteen years in the biomedical research industry. As the Executive Medical Director and Therapeutic Area Medical Lead for Oncology at Allucent, Dr. Abbott oversees clinical trial strategies and medical monitoring for hematology/oncology trials and leads the global oncology medical team at Allucent. His career includes senior medical leadership roles at Myriad Genetics, Caris Life Sciences, and Color Genomics.
Prior to his industry roles, he spent a decade in clinical practice as faculty at three NCCN member institutions, focusing on leukemia, lymphoma, and bone marrow transplantation (BMT), while serving as a principal investigator in numerous oncology studies. Dr. Abbott’s expertise spans CAR T studies in prostate and hepatocellular cancers, TKIs across various indications, bi-specific antibodies, cytotoxic chemotherapy, and vaccine/cellular therapies. He has significant experience with companion diagnostics registration and phase 1 clinical trials.
Dr. Abbott earned his M.D. from the University of Tennessee, an MBA from the University of Colorado, and a master’s degree in finance from the University of Wisconsin. He is board-certified in Hematology/ Oncology, Pediatrics, and Hospice/Palliative Medicine
Dr. Haifeng Chen is a globally recognized pioneer in gene therapy, with over three decades of transformative contributions to adeno-associated virus (AAV) technology and biopharmaceutical innovation. He earned his B.S. in Biology from Sun Yat-sen University (1982), M.S. in Biology from Sichuan University (1985), and Ph.D. from the University of Saarland, Germany (1992). In 1992, he received the prestigious Marion-Merrell-Dow Post Doctoral Fellowship, conducting groundbreaking research at the University of Kansas Medical Center.
Chen’s distinguished career includes leadership roles at leading gene therapy companies, including Cell Genesys, Genovo, Avigen, and Asklepios BioPharmaceutical. In 2006, he co-founded Virovek, serving as Chief Executive Officer until 2019. There, he invented the revolutionary “BAC-to-AAV” system, utilizing baculovirus and Sf9 cells to achieve 10–100x higher AAV yields than traditional plasmid transfection methods, setting a new standard for scalable, high-potency AAV production.
In 2019, Chen co-founded Avirmax, Inc., where he served as Chief Technology Officer and Chief Operating Officer until 2022. Returning to Virovek in August 2022 as Chief Scientific Officer and Vice President, he continues to drive cutting-edge advancements. In 2024, he developed the innovative PACE (Precision AAV Capsid Engineering) technology, enabling precise AAV capsid modifications to target specific cell types based on surface markers. This breakthrough has propelled Virovek to the forefront of in vivo CAR T therapy and solid tumor immunotherapy, with its AAV-based in vivo CAR T therapy yielding successful preclinical data and advancing toward an IND filing by the end of 2025.
A respected figure in the scientific community, Chen has served on the Viral Gene Transfer Vector Committee of the American Society of Gene and Cell Therapy (ASGCT) and the editorial board of Molecular Therapy – Methods and Clinical Development. His visionary leadership and relentless pursuit of innovation continue to shape the future of gene and cell therapy, addressing critical unmet medical needs with transformative solutions
Reagan Jarvis is the co-founder and CEO of Anocca, a T-cell immunotherapy company based out of Sweden, commencing FIH clinical trials in 2025 with TCR-T cell therapy products in oncology. A New Zealander, Jarvis obtained his PhD in Biochemistry at University of Otago and performed postdoctoral research at the University of Otago and thereafter the German Cancer Research Center (DKFZ) in Heidelberg. He founded Anocca with Mikael Blomqvist in 2014.
Anocca currently has a pipeline of 40 products. It has 120+ staff, with 36 nationalities and operates the largest cGMP cell therapy manufacturing site in the Nordics.
Dr. Lawrence Lamb leads scientific and translational strategy as scientific co-founder, Executive Vice President, and Chief Scientific Officer of IN8Bio. While originally extending his NP clinical training in cardiovascular disease as a PhD student, he switched gears and studied immunology, finishing his PhD with a concentration in inflammatory lung disease and macrophage biology followed by postdoctoral training in molecular evolution and genetic engineering of mouse embryonic stem cells to define gene function. During a second postdoc in transplantation immunology at the South Carolina Cancer Center he was the first to describe the association between relapse-free survival and homeostatic γδT cell recovery in high-risk leukemia patients.
While continuing this work as an Associate Professor and later Professor of Medicine at the University of Alabama at Birmingham, Lamb developed the scientific support for chemotherapy resistant γδT cell-based immunotherapy for high grade brain tumors. This work eventually culminated in successful IND applications that lead to the formation of IN8Bio. Over the course of his career, Lamb’s work has been funded by adiverse array of government and the NCI, NHLBI, NCRR, NINDS, the Children’s Oncology Group, the Elsa Pardee Foundation, the Leukemia and Lymphoma Society, and the National Brain Tumor Foundation including the Samuel Gerson Leadership Chair for Glioblastoma Research
Geraldine Paulus co-founded Crossbow Therapeutics in October 2021, while a member of the investment team at MPM Capital (now MPM BioImpact),and has served as Crossbow’s Vice President of Corporate Development and Operations since July 2022. Paulus brings a decade of cross-disciplinary and translational academic experience and spent four years in Venture Capital (The Engine, MPM BioImpact), where she focused on due diligence, business development, and company creation. Paulus holds B.S. and M.S. degrees in Chemical Engineering from the KU Leuven (Belgium), a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT) and was a postdoctoral fellow in Dr. Ramnik Xavier’s lab at Mass General Hospital (MGH) and The Broad Institute.